Pelabresib (BET bromodomain inhibitor)
Current understanding
To be populated as evidence accumulates.
Evidence log
- May 1, 202 — Myelofibrosis (MF) in 2026: Matching Therapy to the Dominant Clinical Problem: Narrative review (2026, review-level) cites phase 3 MANIFEST-2 data showing pelabresib + ruxolitinib improved outcomes over ruxolitinib monotherapy in JAK inhibitor–naïve intermediate-1 or higher-risk MF, supporting the combination as a frontline option matched to proliferative/splenomegaly-dominant disease. (novelty: 3)
- June 12-15 — Advancing Frontiers in Myeloproliferative Neoplasms - EHA 2025 Congress Review: EHA 2025 congress review (review-level) highlights pelabresib + ruxolitinib in the Phase III MANIFEST-2 trial as a featured MF advance, reinforcing the BET + JAK combination as a frontline strategy. (novelty: 3)
- 2026-06-04 — A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies: Phase 1/2 study (trial-early) evaluated pelabresib (CPI-0610) as monotherapy and in combination with ruxolitinib in MF and ET, providing the foundational early clinical safety/efficacy data underpinning the later MANIFEST-2 and Phase 3 MANIFEST-3 programs. (novelty: 3)
- 2026-06-05 — The impact of novel bet inhibitors on the treatment armamentarium of Myelofibrosis.: Review (10-year synthesis) positions pelabresib as the lead BET inhibitor in MF with clinically meaningful phase 2-3 activity complementing JAK inhibition by targeting inflammatory, fibrotic, and proliferative transcriptional programs; hematologic toxicity and long-term survival impact remain unresolved. (novelty: 3)
Open questions
Related
Contributing findings
Myelofibrosis (MF) in 2026: Matching Therapy to the Dominant Clinical Problem
May 1, 2026
novelty 3
per-area 3
strengthens
Advancing Frontiers in Myeloproliferative Neoplasms - EHA 2025 Congress Review
June 12-15, 2025
novelty 3
per-area 4
strengthens
New Drugs in Myelofibrosis: Incremental Progress in Symptom Management Without Disease Modification.
23-oct-2026
novelty 2
per-area 2
strengthens
Emerging agents and regimens for myeloproliferative neoplasms: updates from ASH 2025 Annual Meeting.
03-aug-2026
novelty 2
per-area 3
strengthens
Closing the disease modification gap: Emerging therapies in myelofibrosis beyond JAK inhibition.
30-jul-2026
novelty 2
per-area 2
mentions
Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)
17-jul-2026
novelty 2
per-area 3
strengthens
The impact of novel bet inhibitors on the treatment armamentarium of Myelofibrosis.
05-jun-2026
novelty 3
per-area 4
strengthens
A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies
04-jun-2026
novelty 3
per-area 3
strengthens
🔎 Auto-added searches
| Query | Source | Added | Hits | Rationale |
|---|---|---|---|---|
"pelabresib"[Title/Abstract] OR "CPI-0610"[Title/Abstract] |
pubmed | 21-jun-2026 | 1 / 32 | Targets pelabresib by both its generic name and trial compound identifier, which existing queries (including the BET bromodomain inhibitor query) do not explicitly cover, ensuring retrieval of all clinical and preclinical papers on this specific agent. |
Show 2 demoted
| Query | Source | Demoted | Reason |
|---|---|---|---|
"pelabresib"[Title/Abstract] AND ("ruxolitinib"[Title/Abstract] OR "JAK inhibitor"[Title/Abstract] OR "combination therapy"[Title/Abstract] OR "spleen volume"[Title/Abstract] OR "symptom burden"[Title/Abstract]) AND ("myelofibrosis"[Title/Abstract] OR "myeloproliferative"[Title/Abstract]) |
pubmed | 13-sep-2026 | 0 relevant hits over 10 scans (min 1) |
pelabresib CPI-0610 BET bromodomain myelofibrosis |
biorxiv | 22-jun-2026 | (manual) biorxiv keyword-matching too loose (v1 OR/substring); expansion moved to pubmed-only |